162 related articles for article (PubMed ID: 10448301)
1. FHIT gene abnormalities in both benign and malignant thyroid tumours.
Zou M; Shi Y; Farid NR; al-Sedairy ST; Paterson MC
Eur J Cancer; 1999 Mar; 35(3):467-72. PubMed ID: 10448301
[TBL] [Abstract][Full Text] [Related]
2. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
4. Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine triad (FHIT) gene is associated with features of differentiated thyroid carcinoma.
Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen RL; Gao JX; He G
Ann Clin Lab Sci; 2010; 40(3):267-72. PubMed ID: 20689140
[TBL] [Abstract][Full Text] [Related]
5. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 3p tumor-suppressor gene alterations in cervical carcinomas.
Herzog CR; Crist KA; Sabourin CL; Kelloff GJ; Boone CW; Stoner GD; You M
Mol Carcinog; 2001 Mar; 30(3):159-68. PubMed ID: 11301476
[TBL] [Abstract][Full Text] [Related]
7. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SKG; Wang L; Hay ID; Yokomizo ; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-757. PubMed ID: 28796361
[TBL] [Abstract][Full Text] [Related]
8. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
9. Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites.
Manning AP; Mes-Masson AM; Seymour RJ; Tetrault M; Provencher DM; Tonin PN
Mol Carcinog; 1999 Mar; 24(3):218-25. PubMed ID: 10204806
[TBL] [Abstract][Full Text] [Related]
10. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines.
Mao L; Fan YH; Lotan R; Hong WK
Cancer Res; 1996 Nov; 56(22):5128-31. PubMed ID: 8912845
[TBL] [Abstract][Full Text] [Related]
11. Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas.
Hilgers W; Groot Koerkamp B; Geradts J; Tang DJ; Yeo CJ; Hruban RH; Kern SE
Genes Chromosomes Cancer; 2000 Mar; 27(3):239-43. PubMed ID: 10679912
[TBL] [Abstract][Full Text] [Related]
12. Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type.
Muller CY; O'Boyle JD; Fong KM; Wistuba II; Biesterveld E; Ahmadian M; Miller DS; Gazdar AF; Minna JD
J Natl Cancer Inst; 1998 Mar; 90(6):433-9. PubMed ID: 9521167
[TBL] [Abstract][Full Text] [Related]
13. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines.
Simon B; Bartsch D; Barth P; Prasnikar N; Münch K; Blum A; Arnold R; Göke B
Cancer Res; 1998 Apr; 58(8):1583-7. PubMed ID: 9563464
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck.
Kisielewski AE; Xiao GH; Liu SC; Klein-Szanto AJ; Novara M; Sina J; Bleicher K; Yeung RS; Goodrow TL
Oncogene; 1998 Jul; 17(1):83-91. PubMed ID: 9671317
[TBL] [Abstract][Full Text] [Related]
15. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).
Zou TT; Lei J; Shi YQ; Yin J; Wang S; Souza RF; Kong D; Shimada Y; Smolinski KN; Greenwald BD; Abraham JM; Harpaz N; Meltzer SJ
Oncogene; 1997 Jul; 15(1):101-5. PubMed ID: 9233782
[TBL] [Abstract][Full Text] [Related]
16. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours.
Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C
Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528
[TBL] [Abstract][Full Text] [Related]
17. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
Shi Y; Zou M; Farid NR; al-Sedairy ST
Br J Cancer; 1996 Nov; 74(9):1336-41. PubMed ID: 8912526
[TBL] [Abstract][Full Text] [Related]
18. Loss of FHIT expression in gastric carcinoma.
Baffa R; Veronese ML; Santoro R; Mandes B; Palazzo JP; Rugge M; Santoro E; Croce CM; Huebner K
Cancer Res; 1998 Oct; 58(20):4708-14. PubMed ID: 9788626
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos.
Nelson HH; Wiencke JK; Gunn L; Wain JC; Christiani DC; Kelsey KT
Cancer Res; 1998 May; 58(9):1804-7. PubMed ID: 9581816
[TBL] [Abstract][Full Text] [Related]
20. Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines.
Ong ST; Fong KM; Bader SA; Minna JD; Le Beau MM; McKeithan TW; Rassool FV
Genes Chromosomes Cancer; 1997 Sep; 20(1):16-23. PubMed ID: 9290949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
